Possible relationship between refractory celiac disease and malignancies

Kaan Demiroren

Abstract

Celiac disease (CeD) is a chronic autoimmune disorder that is triggered by gluten in genetically susceptible individuals, and that is characterized by CeD-specific antibodies, HLA-DQ2 and/or HLA-DQ8 haplotypes, enteropathy and different clinical pictures related to many organs. Intestinal lymphoma may develop as a result of refractory CeD. If a patient diagnosed with CeD is symptomatic despite a strict gluten-free diet for at least 12 months, and does not improve with severe villous atrophy, refractory CeD can be considered present. The second of the two types of refractory CeD has abnormal monoclonal intraepithelial lymphocytes and can be considered as pre-lymphoma, and the next picture that will emerge is enteropathy-associated T-cell lymphoma. This manuscript addresses "CeD and malignancies" through a review of current literature and guidelines.

Key Words: Refractory celiac disease; Enteropathy-associated T-cell lymphoma; Pre-lymphoma; Low grade lymphoma

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
INTRODUCTION

Celiac disease (CeD) is a chronic autoimmune disorder that is triggered by gluten in genetically susceptible persons with HLA-DQ2 and/or HLA-DQ8 haplotypes, and is characterized by CeD-specific antibodies and enteropathy[1-3]. The prevalence of CeD in the general population is approximately 1% on serological screening, and 0.6% as histologically confirmed[3].

CeD can affect many organs, and can cause or trigger, or be associated with different clinical pictures, including growth retardation, short stature, chronic diarrhea, constipation[1], iron deficiency anemia[4], dermatitis herpetiformis[5], dental enamel defects[6], aphthous stomatitis[7], rickets, osteoporosis[6,9], arthralgia, arthritis[10], idiopathic epilepsy[11], peripheral neuropathy[12], ataxia[13], abnormal liver tests, autoimmune hepatitis[14], type1 diabetes mellitus[15], IgA deficiency[16], psychiatric comorbidities[17], intestinal lymphoma[3], etc. It is not known exactly why these clinical pictures emerge as different manifestations in different patients, as there are complex underlying mechanisms. Although the relationship between CeD and intestinal lymphoma is known, there have been many studies and case reports suggesting its association with other malignancies. For the present manuscript, a systematic literature search of PubMed/MEDLINE was carried out using the search terms “Celiac disease AND guideline, and Celiac disease AND malignancy” and a review was made on the subject of “CeD and malignancies” in current literature and guidelines in line with the following structure: (1) Pathogenesis of CeD; (2) Refractory CeD; (3) Enteropathy-associated T-cell lymphoma (EATL); (4) CeD and malignancies; and (5) Conclusion.

PATHOGENESIS OF CELIAC DISEASE

Although the pathogenesis of CeD is not fully understood, it is considered to be attributable to the coaction of genetic, environmental and immunologic factors. The HLA-DQ2 and/or HLA-DQ8 haplotypes are necessary for CeD development. Studies have shown that around 4% of HLA-DQ2 + cases develop CeD, and that HLA-DQ2 and HLA-DQ8 negative CeD development is extremely rare[18]. It is evident that environmental factors are at the core of the CeD pathogenesis, of which gluten is the sine qua non trigger. The gliadin proteins found in gluten are composed of glutenine and prolamine residues, and cannot be fully digested, even in a healthy person. HLA-DQ2 and HLA-DQ8 proteins are located on the surface of intestinal antigen-presenting cells. Undigested gliadin peptides in the intestinal lumen pass through the intestinal epithelium and undergo cross-linking and deamination through tissue transglutaminase (tTG) in the lamina propria. The glutenamine contained within gliadin is converted to glutamic acid, bound to HLA-DQ2 and HLA-DQ8 and presented to CD4+ T cells. The cross-linking of gliadin and tTG results in the formation of tTG antibodies that impair the function of tTG. Activated CD4+ T cells cause the production of pro-inflammatory cytokines like interferon-γ that contain T-helper cells that worsen the inflammatory effect in the process. Matrix metalloproteinases cause the degradation of the extracellular matrix and damage to the basement membranes, resulting in an increase in natural killer (NK) T lymphocytes within the epithelial cell. Gliadins also upregulate the expression of the zonulin protein by increasing intestinal permeability in both CeD patients and healthy people. Increased anti-tTG levels are also known to inhibit ITG and make gliadin harder to digest, which in turn increases tTG activity, resulting in a vicious cycle. Intraepithelial lymphocytes (IELs) include T cell receptor (TCR)αβ+ and αβδ+ T cells, and NK cells. Most of these TCR+ IELs express a variety of NK cell receptors, and in addition, the number of CD8+ TCRδβ+ and TCRγδ+ increases. Consequently, characteristic lesions of CeD develop by apoptosis[2,18-22].

CeD is in general similar to other autoimmune diseases, but has a very clear and indispensable trigger: gluten. Gluten-induced intestinal lesions and autoantibodies begin to improve in the absence of gluten. Anti-tTG antibodies increase to protect against the disease, and are at the center of the pathogenesis. They may appear before villous atrophy develops and can induce CeD[21].

REFRACTORY CeD

Refractory CeD (RCeD) patients are those with a pre-existing diagnosis of CeD whose CeD-related symptoms fail to improve, and in whom villous atrophy develops despite a strict gluten-free diet for more than 12 months[23-25]. RCeD is mostly diagnosed after the age of 50 years, but younger cases have
been identified. The incidence for both types of RCeD is in the 0.04%-1.5% range[3].

When RCeD is suspected, a second endoscopy and several biopsies are mandatory. Duodenal biopsies show Marsh type III, and sometimes Marsh type II[3]. The presence of subepithelial collagen extending to the lamina propria in the duodenal second part, chronic inflammation and crypt hypoplasia (not hyperplasia) with villous atrophy are common microscopic findings of RCeD[23].

Refractory CeD is divided histologically into two subgroups according to the immunophenotype of IELs: type I (RCeD-1) and type 2 (RCeD-2). RCeD-1 has a normal intraepithelial lymphocyte phenotype while RCeD2 has an abnormal clonal lymphocyte population[25]. In RCeD-1, the symptoms are less severe, and the endoscopic and histological features are similar to active uncomplicated CeD. RCeD-1 shows the same normal immunophenotype as CeD, often leading to difficulties in differential diagnosis from CeD, although differentiating between RCeD-1 and RCeD-2 is mandatory due to the different treatment strategies and prognosis[3].

The immunophenotype of abnormal IELs in RCeD-2 is different to that of RCeD-1. It has been reported that interleukin-15 and somatic mutations in JAK1 or STAT3 in the proliferation of aberrant T cells play an important role in the formation of RCeD-2[24]. Cording et al[26] identified a complex mutational profile of JAK1 and STAT3 that activated the NF-κB pathway in CeD-associated lymphomagenesis.

While most lymphocytes express CD3, CD8 and polyclonal TCRβ, RCeD-2 is characterized by abnormal T cells that do not express surface CD3 or CD8, but instead express intracellular CD3 by a TCR gamma rearrangement[23-25], and these cells also express NK surface markers[24,27]. RCeD-1 becomes involved when abnormal T cells account for less than 20%, and RCeD-2 for more than 20%. RCeD-2 may be referred to as pre-lymphoma or low grade lymphoma due to the high risk of conversion to EATL[3,28]. Verbeeck et al[29] suggest that the quantification of abnormal T cells using flow cytometry is preferable to T cell clonality analyses in differentiating RCeD patients. The use of a cut-off value of 20% for the classification of patients can also support the selection of long-term follow-up and treatment.

Figure 1 summarizes the properties of RCeD-1, RCeD-2 and EATL.

The goal of treatment is to prevent RCeD-1 patients from converting to RCeD-2, and then to EATL, in that a total of 52% of RCeD-2 patients have been reported to develop EATL within 4-6 years of diagnosis of RCeD-2[30]. Immunosuppressive drugs are used together with nutritional support for the treatment of RCeD-1. Although similar therapies have been applied for RCeD-2, their usefulness is limited. In such patients, autologous hematopoietic stem cell transplantation following high-dose chemotherapy is an alternative treatment[3,31].

**ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA**

Enteropathy-associated T-cell lymphoma accounts for less than 1% of all non-Hodgkin lymphomas, and as such is considered a rare GI lymphoma[3]. Approximately 50% of RCeD-2 patients are thought to develop overt lymphoma within 5 years of diagnosis[18]. EATL occurs predominantly in patients in the sixth and seventh decades, and usually develops in those diagnosed with CeD[25,32,33]. EATL is thought to be derived from IELs, and the abnormal immune phenotype of IELs seen in RCeD-2 indicates early-stage lymphoma development. To date, two histologically subtypes of EATL have been described[23].

A microscopic examination of type I EATL (EATL-1) reveals transmural infiltration including pleomorphic medium- to large-size neoplastic lymphocytes, histiocytes and eosinophils. Mitotic figures and necrosis are common, and enteropathic changes such as villous atrophy, crypt hyperplasia and intraepithelial lymphocytosis may be seen in the non-tumor gastrointestinal tract mucosa[25,33]. Tumor cells in EATL-1 have a pattern of CD2+, CD3+, CD5-, CD4+, CD7+, CD8-, CD56-, TCR- (usually), CD103+ and CD30+ (often), and a high Ki-67 proliferative index and p53 expression. Epstein-Barr virus is negative[33]. In some cases, tumor cells may show pronounced pleomorphism reminiscent of anaplastic large cell lymphoma or Hodgkin lymphoma[23]. The IELs in the non-neoplastic mucosa have the same immunophenotype as in RCeD-2. Type 2 EATL (EATL-2) is rare, and is generally not associated with a previous diagnosis of CeD[3]. While the features of non-tumoral mucosa resemble those of CeD, the tumor cells in EATL-2 have a CD3+, CD8+, CD56- or CD4- pattern. NKP46, indicating progression from RCeD-2, has also been reported in EATL[23].

**CeD AND MALIGNANCIES**

The increased risk of malignant lymphomas in CeD is correlated to small bowel histopathology, and so no increased risk of lymphoma is expected in CeD patients with improved intestinal mucosal changes and with a gluten-free diet, or in potential CeD patients with an already normal intestinal mucosa[34]. Goerres et al[35] found intestinal UDP-glucuronosyltransferases, which are involved in the detoxification of ingested toxins and carcinogens, to be decreased in CeD, and suggested that this could
Celiac disease and malignancies

Demiroren K. Celiac disease and malignancies
WJCO
https://www.wjgnet.com
203
March 24, 2022
Volume 13
Issue 3

Demiroren K. Celiac disease and malignancies

Figure 1 Properties of refractory celiac disease type 1, type 2 and enteropathy-associated T-cell lymphoma. RCeD: Refractory celiac disease; EATL: Enteropathy-associated T-cell lymphoma; IEL: Intraepithelial lymphocytes; TCR: T cell receptor.

potentially pose a risk of cancer. Kamycheva et al[36] reported the leukocyte telomere length to be shorter in CeD seropositive patients, which may indicate genomic instability – a well-known predisposing factor of genetic changes and eventual carcinogenesis.

Ferguson et al[37] reported a 1.9 times greater risk of mortality in 653 CeD patients after a mean follow-up of 13.5 years, with the most common causes of death being lymphoproliferative disease and esophageal cancer. Freeman[38] identified 8.4% lymphoma, 1.4% small bowel carcinoma and 0.5% hypopharyngeal carcinoma in 214 patients with CeD, and reported the risk of lymphoma and small bowel adenocarcinoma to be increased especially in patients diagnosed with CeD after the age of 60 years, suggesting that risk increases the longer the diagnosis of CeD is delayed. Howdle et al[32] reported 13% of adenocarcinoma cases and 39% of lymphomas to have CeD.

Grainge et al[39] reported in their cohort study that the risk of any malignancy in CeD patients was 40% greater than in the general population, with an average follow-up of 25 years. They reported the highest risk in those with non-Hodgkin’s lymphomas, with an overall incidence of 1.3 per 1000 person-years, but that the overall malignancy risk did not increase significantly 15 years after the diagnosis of CeD. Eigner et al[40] identified RCeD in 2.6% of 1,138 CeD patients, and reported that in 29 RCeD patients followed for 25 years, RCeD-1 developed in 1.3%, RCeD-0.6%, EATL in 0.6% and small intestine adenocarcinoma in 0.4%, with a mortality rate of 48%. They noted further that in the preceding five years, there had been no patients diagnosed with RCeD-2, EATL or small bowel adenocarcinoma, which could be related to the increased awareness of CeD and strict adherence to a gluten-free diet.

Green et al[41] reported detecting small bowel adenocarcinoma in two (0.2%) and non-Hodgkin’s lymphoma in five (0.4%) of 1,612 CeD patients, with EATL being found in three patients (relative risk was 300). In a meta-analysis Han et al[42] reported a pooled odds ratio (OR) for the risk of all malignancies of 1.25, and 1.60 for GI malignancy in CeD patients. Of the GI malignancies, esophageal cancer (pooled OR= 3.72) and small intestinal carcinoma (pooled OR = 14.41) were associated with a greater risk. Ilus et al[43] reported that the standardized incidence ratio (SIR) did not increase for the series as a whole in 32,439 CeD patients, but reported a decrease in breast and lung cancers, and an increase in NHL (SIR: 1.94) and small bowel cancers (SIR: 4.29) 5 years after the CeD diagnosis. In a recent study, Koskinen et al[44] reported that although the overall mortality in adult CeD diagnosed in 2005–2014 had not increased, mortality associated with lymphoproliferative diseases had increased, but to a lesser degree than previously reported.

Table 1 provides details of studies of malignancies in CeD patients, including those identifying and not identifying an increased risk. The malignancies associated with CeD in the case reports are presented in Table 2.

CONCLUSION

A causal relationship between CeD and EATL2 has been proven. Although its relationship with other cancer types is controversial, considering the pathogenesis of CeD, such a possibility can be considered.
**Table 1 Malignancies with increased risk, or not reported in studies of patients with celiac disease**

| Ref. | Study design | Increased risk | No increased risk |
|------|--------------|----------------|-------------------|
| Eigner et al [40] | Retrospective cohort | EATL | - |
| | | Small bowel adenocarcinoma | |
| Freeman[38] | Retrospective cohort | Lymphoma | - |
| | | Small bowel carcinoma | |
| | | Hypopharyngeal carcinoma | |
| Grainge et al [39] | Cohort | All malignancies | - |
| | | Non-Hodgkin’s lymphoma | |
| Howdle et al [32] | Survey | Small bowel adenocarcinoma | - |
| | | Small bowel lymphoma | |
| van Gils et al [47] | Case-control | T-cell lymphoma, predominantly EATL | Other types of lymphomas |
| | | Small bowel adenocarcinoma | GI carcinomas |
| | | Esophageal squamous cell carcinoma | |
| Anderson et al [48] | Retrospective cohort | Non-Hodgkin’s lymphoma (but not statistically significant) | - |
| Green et al [41] | National survey | Small bowel adenocarcinoma | - |
| | | Non-Hodgkin’s lymphoma | |
| Han et al [42] | Meta-analysis | All malignancies | Other GI cancers |
| | | Small intestinal cancers | |
| | | Esophageal cancer | |
| Ilus et al [43] | Retrospective cohort | Non-Hodgkin lymphoma | Decreased risk of lung, pancreatic, bladder, renal and breast cancer |
| | | Small intestinal cancer | Colon cancer |
| | | Basal cell carcinoma of the skin | |
| Kent et al [49] | Cohort | Papillary thyroid cancer | - |
| Lebwold et al [50] | Population-based setting | - | Cutaneous malignant melanoma |
| Volta et al [51] | Cohort | - | Colon carcinoma |

EATL: Enteropathy-associated T-cell lymphoma; GI: Gastrointestinal; OR: Odds ratio; RR: Relative risk.

Studies have suggested that this risk is gradually decreasing[38,39] due to the increased awareness of CeD over the years, and the widespread use of diagnostic tests and endoscopy, which have made diagnosis easier and more common. Furthermore, the increase in the availability of commercial gluten-free products has facilitated stricter compliance with gluten-free diets. Today, the follow-up of CeD patients at certain periods is recommended in CeD guidelines[1,45]. In the event of suspected non-compliance with a gluten-free diet, or when presented with symptoms, the patient is re-evaluated with CeD-specific antibodies and the presence of RCeD is investigated. The major limitation of most of the above-mentioned studies is the lack of reporting on the compliance of CeD patients with the diet "assessed from year to year" based on CeD-specific tests. Indeed, in some of the studies, the CeD diagnosis was made either together or recently in some of the patients diagnosed with lymphoma at elderly ages. For this reason, objective evaluations (monitoring with CeD-specific antibodies or measurement of gluten immunogenic peptides in urine and feces[46]) of CeD patients diagnosed in childhood will yield better results. In addition to the above, since intestinal villous atrophy improves with a gluten-free diet, an early diagnosis of CeD and a lifelong gluten-free diet are very important in preventing the formation of intestinal lymphoma and adenocarcinoma. Regular follow-ups can support patients in their compliance with a gluten-free diet.
Table 2 Malignancies associated with celiac disease in case reports

| Ref.          | Diagnosis of malignancies (age in years)                                      |
|--------------|--------------------------------------------------------------------------------|
| Ahluwalia et al[52] | Burkitt-like lymphoma of colon (75)                                     |
| Buess et al[53]   | EATL causing obstructive jaundice (54)                                   |
| Cankurtaran et al[54] | Plasma cell dyscrasia (65)                                             |
| Cereda et al[55]  | 1st patient: Burkitt lymphoma of the small bowel (5)                     |
|                | 2nd patient: Ependymoma (4)                                              |
|                | 3rd patient: Ewing sarcoma (6)                                            |
| Zunguo et al[56] | Large B-cell lymphoma and enteropathy-type T-cell lymphoma (65)          |
| Fallah et al[57] | Adenocarcinoma of the small intestine (89)                               |
| Jafroodi et al[58] | Hodgkin’s lymphoma (11)                                                  |
| Naderi et al[59]   | Two patients: germ cell tumor (3.5 and 5)                               |
|                | 3rd patient: Wilms’s tumor (6)                                            |
|                | 4th patient: Acute lymphoblastic lymphoma (4.5)                          |
|                | 5th patient: Astrocytoma (8)                                             |
| Sahin et al[60]  | Intestinal adenocarcinoma (58)                                           |
| Zuillo et al[61]  | Intestinal adenocarcinoma (77)                                           |

FOOTNOTES

Author contributions: Demiroren K solely contributed to this manuscript.

Conflict-of-interest statement: The author declares that no conflicts of interest, financial or otherwise, exist related to this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Turkey

ORCID number: Kaan Demiroren 0000-0003-1137-1715.

S-Editor: Gong ZM

L-Editor: A

P-Editor: Gong ZM

REFERENCES

1 Husby S, Koletzko S, Korponay-Szabó IR, Meairn ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D, Catassi C, Lelgeman M, Mäki M, Ribes-Konincx C, Ventura A, Zimmer KP; ESPGHAN Working Group on Coeliac Disease Diagnosis; ESPGHAN Gastroenterology Committee; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. *J Pediatr Gastroenterol Nutr* 2012; 54: 136-160 [PMID: 22197856 DOI: 10.1097/MPG.0b013e31821a23d0]

2 Kupfer SS, Jabri B. Pathophysiology of celiac disease. *Gastrointest Endosc Clin N Am* 2012; 22: 639-660 [PMID: 23083984 DOI: 10.1016/j.gie.2012.07.003]

3 Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, Mulder CJ, Lundin KEA. European Society for the Study of Coeliac Disease (EScCD) guideline for coeliac disease and other gluten-related disorders. *United European Gastroenterol J* 2019; 7: 583-613 [PMID: 31210940 DOI: 10.1177/2050640619844125]

4 Karaman K, Akbayram S, Kar S, Demirören K. Prevalence of Celiac Disease in Children With Iron Deficiency Anemia in Van Lake Region of Turkey. *J Pediatr Hematol Oncol* 2016; 38: 143-146 [PMID: 26808365 DOI: 10.1097/MPH.0000000000000495]
[PMID: 17470479] DOI: 10.1136/gut.2006.114512

Al-toma A, Visser OJ, van Roessel HM, von Blomberg BM, Verbeek WH, Scholten PE, Ossenkoppele GJ, Huigjens PC, Mulder C.J. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. *Blood* 2007; 109: 2243-2249 [PMID: 17068146] DOI: 10.1182/blood-2006-08-042820

Howdle PD, Jalal PK, Holmes GK, Houlston RS. Primary small-bowel malignancy in the UK and its association with coeliac disease. *QJM* 2003; 96: 345-353 [PMID: 12702783] DOI: 10.1093/qjmed/hcg056

Foukas PG, Bisig B, de Leval L. Recent advances upper gastrointestinal lymphomas: molecular updates and diagnostic implications. *Histopathology* 2021; 78: 187-214 [PMID: 33382405] DOI: 10.1111/his.14209

Elfrom P, Granath F, Ekstrom Smedby K, Montgomery SM, Asling K, Ekbom A, Ludvigsson JF. Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. *J Natl Cancer Inst* 2011; 103: 436-444 [PMID: 21289299] DOI: 10.1093/jnci/djq564

Goeres M, Roelofs HM, Jansen JB, Peters WH. Deficient UDP-galactosyltransferase detoxification enzyme activity in the small intestinal mucosa of patients with coeliac disease. *Aliment Pharmacol Ther* 2006; 23: 243-246 [PMID: 16393303] DOI: 10.1111/j.1365-2366.2006.02754.x

Kamycheva E, Goto T, Camargo CA Jr. Celiac disease autoimmunity is associated with leukocyte telomere shortening in older adults: The U.S. National Health and Nutrition Examination Survey. *Exp Gerontol* 2017; 89: 64-68 [PMID: 28104447] DOI: 10.1016/j.exger.2017.01.003

Ferguson A, Kingstone K. Coeliac disease and malignancies. *Acta Paediatr Suppl* 1996; 412: 78-81 [PMID: 8783767] DOI: 10.1111/j.1651-2227.1996.tb14259.x

Freeman HJ. Lymphoproliferative and intestinal malignancies in 214 patients with biopsies-defined celiac disease. *J Clin Gastroenterol* 2004; 38: 429-434 [PMID: 15100523] DOI: 10.1097/00004836-200405000-00308

Grange MJ, West J, Solaymani-Dodaran M, Card TR, Logan RF. The long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study. *Aliment Pharmacol Ther* 2012; 35: 730-739 [PMID: 2288441] DOI: 10.1111/j.1365-2036.2012.04998.x

Eigner W, Bashir K, Primas C, Kazemi-Shirazi L, Wrba F, Trauner M, Vogelsang H. Dynamics of occurrence of refractory coeliac disease and associated complications over 25 years. *Aliment Pharmacol Ther* 2017; 45: 364-372 [PMID: 27885681] DOI: 10.1111/apt.13867

Green PHR, Stavropoulos SN, Panagi SG, Goldstein SL, Memahan DJ, Abaan H, Neugut AI. Characteristics of adult celiac disease in the USA: results of a national survey. *J Gastroenterol* 2001; 96: 126-131 [PMID: 11197241] DOI: 10.1111/j.1572-0241.2001.00346.x

Han Y, Chen W, Li P, Ye J. Association between Coeliac Disease and Risk of Any Malignancy and Gastrointestinal Malignancy: A Meta-Analysis. *Medicine (Baltimore)* 2015; 94: e1612 [PMID: 26402826] DOI: 10.1097/MD.0000000000001612

Ilus T, Kaukinen K, Virta LJ, Puikala E, Collin P. Incidence of malignancies in diagnosed celiac patients: a population-based estimate. *Am J Gastroenterol* 2014; 109: 1471-1477 [PMID: 25047399] DOI: 10.1038/ajg.2014.194

Koskinen I, Virta LJ, Huhtala H, Ilus T, Kaukinen K, Collin P. Overall and Cause-Specific Mortality in Adult Celiac Disease and Dermatitis Herpetiformis Diagnosed in the 21st Century. *J Am Geriatr Soc* 2014; 115: 1117-1124 [PMID: 23616683] DOI: 10.1111/jgs.13065

Hussy S, Murray JA, Katzka DA. AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease-Changing Utility of Serology and Histologic Measures: Expert Review. *Gastroenterology* 2019; 156: 885-889 [PMID: 30578783] DOI: 10.1053/j.gastro.2018.12.010

Ruiz-Carnicer A, Garzón-Benavides M, Fombuena B, Segura V, García-Fernández F, Sobrino-Rodríguez S, Gómez-Izquierdo L, Montes-Canino MA, Rodríguez-Herrera A, Millán R, Raco MC, González-Narváez C, Bozada-García JM, Díaz J, Coronel-Rodríguez C, Espín B, Romero-Gómez M, Cebolla Á, Sousa C, Comino I, Argüelles F, Pizarro Á. Negative predictive value of the repeated absence of gluten immunogenic peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for follow-up in celiac disease. *J Clin Gastroenterol* 2020; 112: 1240-1251 [PMID: 32692806] DOI: 10.1093/jcn/nqaa188

van Gils T, Nijboer P, Overbeek LI, Hauptmann M, Castelijn DA, Bouna G, Mulder CJ, van Leeuwen FE, de Jong D. Risks for lymphoma and gastrointestinal carcinoma in patients with newly diagnosed adult-onset celiac disease: Consequences for follow-up: Celiac disease, lymphoma and GI carcinoma. *United European Gastroenterol J* 2018; 6: 1485-1495 [PMID: 30574319] DOI: 10.1177/2050640618800540

Anderson LA, McMillan SA, Watson RG, Monaghan P, Gavin AT, Fox C, Murray LJ. Malignancy and mortality in a population-based cohort of patients with celiac disease or “gluten sensitivity”. *World J Gastroenterol* 2007; 13: 146-151 [PMID: 17206762] DOI: 10.3748/wjg.v13.i1.146

Kent L, McBride R, McConnell R, Neugut AJ, Bhagat G, Green PH. Increased risk of papillary thyroid cancer in celiac disease. *Dig Dis Sci* 2006; 51: 1875-1877 [PMID: 16957996] DOI: 10.1007/s10620-006-9240-z

Lebwohl B, Eriksson H, Hansson J, Green PH, Ludvigsson JF. Risk of cutaneous malignant melanoma in patients with celiac disease: a population-based study. *J Am Acad Dermatol* 2014; 71: 245-248 [PMID: 24792461] DOI: 10.1016/j.jaad.2014.03.020

Volta U, Vincentini O, Quintarelli F, Felli C, Silano M. Collaborating Centres of the Italian Registry of the Complications of Celiac Disease. Low risk of colon cancer in patients with celiac disease. *Scand J Gastroenterol* 2014; 49: 564-568 [PMID: 24621303] DOI: 10.3109/03005652.2014.893012

Ahuwalia M, Gotlieb V, Damerla V, Saif MW. Aggressive Burkitt-like lymphoma of colon in a patient with prior celiac disease. *J Gastrointest Oncol* 2016; 7: 259-264 [PMID: 27885681] DOI: 10.1111/j.1365-2366.2016.02754.x

Buess M, Steuerwald M, Wegmann W, Rothen M. Obstructive jaundice caused by enteropathy-associated T-cell lymphoma in a patient with celiac sprue. *J Gastroenterol* 2004; 39: 1110-1113 [PMID: 15580407] DOI: 10.1007/s00535-004-1453-3

Cankurtaran M, Ulger Z, Doğan S, Balam Yavuz B, Halil M, Güllü I, Gedikoğlu G, Anıoğlu S. Complications due to late diagnosis of celiac disease with coexisting plasma cell dyscrasia in an elderly patient. *Aging Clin Exp Res* 2006; 18: 75-77 [PMID: 16608140] DOI: 10.1007/BF03324644
Cereda S, Cefalo G, Sprefico F, Catania S, Meazza C, Podda M, Terenziani M. Celiac disease and childhood cancer. *J Pediatr Hematol Oncol* 2006; 28: 346-349 [PMID: 16794501 DOI: 10.1097/00043426-200606000-00005]

Du Z, Chen J, Zhou X, Zhang T, Chen B, Tang F. Composite lymphoma with relapse of enteropathy-type T-cell lymphoma. *Leuk Lymphoma* 2009; 50: 749-756 [PMID: 19330653 DOI: 10.1080/10428190902795519]

Fallah J, Afari ME, Cordova AC, Olszewski AJ, Minami T. Small Bowel Adenocarcinoma as the Cause of Gastrointestinal Bleeding in Celiac Disease: A Rare Malignancy in a Common Disease. *Case Rep Oncol Med* 2015; 2015: 865383 [PMID: 26290763 DOI: 10.1155/2015/865383]

Fallah J, Afari ME, Cordova AC, Olszewski AJ, Minami T. Small Bowel Adenocarcinoma as the Cause of Gastrointestinal Bleeding in Celiac Disease: A Rare Malignancy in a Common Disease. *Case Rep Oncol Med* 2015; 2015: 865383 [PMID: 26290763 DOI: 10.1155/2015/865383]

Jafroodi M, Zargari O, Hoda S. Concomitant Hodgkin's lymphoma and atopic dermatitis in a child with Celiac disease. *Arch Iran Med* 2009; 12: 317-319 [PMID: 19400614]

Naderi M, Shahramian I, Delaramnasab M, Bazi A. Coincidence of celiac disease with nongastrointestinal tumors in children. *Pediatr Hematol Oncol* 2017; 34: 478-482 [PMID: 29219666 DOI: 10.1080/08880018.2017.1404171]

Sahin C, Ozseker B, Sagiroglu T, Cullu N. Intestinal invagination secondary to intestinal adenocarcinoma in coeliac disease. *BMJ Case Rep* 2015; 2015 [PMID: 25878228 DOI: 10.1136/bcr-2014-208703]

Zullo A, De Francesco V, Manta R, Ridola L, Lorenzetti R. A Challenging Diagnosis of Jejunal Adenocarcinoma in a Celiac Patient: Case Report and Systematic Review of the Literature. *J Gastrointestin Liver Dis* 2017; 26: 411-415 [PMID: 29253057 DOI: 10.15403/jgld.2014.1121.264.zet]
